Experimental drug KZR-261 tested in patients with advanced cancers
NCT ID NCT05047536
First seen Jan 03, 2026 · Last updated May 22, 2026 · Updated 26 times
Summary
This early-phase study tested a new drug called KZR-261 in 61 people with advanced solid tumors (like melanoma, colorectal, or prostate cancer) that had stopped responding to standard treatments. The main goals were to check the drug's safety, find the best dose, and see if it could shrink tumors. The study was stopped early, so results are limited, but it aimed to control the disease rather than cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED / METASTATIC SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cedars Sinai Medical Center
Los Angeles, California, 90048, United States
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
START (South Texas Accelerated Research Therapeutics)
San Antonio, Texas, 78229, United States
-
Sara Cannon Research Institution (SCRI) - Tennessee Oncology Nashville
Nashville, Tennessee, 37203, United States
-
University Hospitals - Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
University of California Los Angeles
Los Angeles, California, 90095, United States
-
Virginia Cancer Specialists (VCS)
Fairfax, Virginia, 22031, United States
-
Winship Cancer Institute of Emory University
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.